Form D · Pharmaceuticals
Sideris Pharmaceuticals, Inc.
Boston, MA · CIK 0001587658
Offering snapshot reported Oct 24, 2013 · SEC filing
- Reported sold
- $17M Offering amount: $32M
- Investors reported
- 6 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Oct 10, 2013 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 24, 2013 | Initial | $17,000,004 | No comparison | 6 | SEC filing |
| Sep 27, 2013 | Initial | $599,000 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-205211
Source: Form D, filed Oct 24, 2013. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Ansbert K Gadicke | Director |
| Thomas Neenan | Director, Promoter |
| Douglas Reed | Director |
| Kazumi Shiosaki | Director, Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
C/O Mpm Capital 200 Clarendon Street, 54 Th Floor
Boston, MA, 02116
Boston, MA, 02116